The results show that the percentage of CD86+ DCs decreased in PB (41.2% vs 21.5%, P = 0.0011) and BM (30.9% vs 12.45%, P = 0.0207) of DN-CML patients compared to controls. Here, CD86 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.